Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Dec 20, 2025; 15(4): 109762
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.109762
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.109762
Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea
Jyoti Bajpai, Department of Respiratory Medicine, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India
Mehul Saxena, Gandhi Memorial Hospital, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India
Utkarsh Agarwal, Faculty of Medical Sciences, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India
Akshyaya Pradhan, Department of Cardiology, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India
Author contributions: Bajpai J and Pradhan A conceived the project; Saxena M and Agarwal U performed the literature search and prepared the first draft; Bajpai J and Saxena M finalised the draft and prepared the revision; Pradhan A critically reviewed the first draft and submitted the final version; and all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Akshyaya Pradhan, Department of Cardiology, King George’s Medical University, Shahmina Road, Chowk, Lucknow 226003, Uttar Pradesh, India.
Received: May 21, 2025
Revised: June 11, 2025
Accepted: October 11, 2025
Published online: December 20, 2025
Processing time: 212 Days and 15.4 Hours
Revised: June 11, 2025
Accepted: October 11, 2025
Published online: December 20, 2025
Processing time: 212 Days and 15.4 Hours
Core Tip
Core Tip: Obstructive sleep apnea (OSA) is a serious sleep disorder often caused by obesity. Standard treatments like continuous positive airway pressure can help, but many people struggle to use them long term. Tirzepatide, a new medication that targets both glucagon-like peptide-1 and gastric inhibitory polypeptide receptors, offers a different approach. By helping with significant weight loss and improving breathing during sleep, tirzepatide has shown strong results in the SURMOUNT-OSA trial, making it the first approved drug to directly treat obesity-related OSA.